SiteOne Therapeutics, a biotechnology company specializing in small molecule inhibitors of sodium channels for treating pain and other neuronal hyperexcitability disorders, is set to be acquired by Eli Lilly. The acquisition agreement states that SiteOne shareholders could receive up to $1 billion in cash. This amount includes an upfront payment as well as additional payments contingent upon achieving specific regulatory and commercial milestones.
The legal team from Cooley LLP advised SiteOne Therapeutics on this transaction. The Cooley team was led by lawyers Laura Berezin, Sara Semnani, Rowook Park, Charity Williams, Rena Kaminsky, Todd Gluth, Lila Hope, Noel Ripberger-Scheick, Tucker Cochenour, and Kristen O’Hanlon.
Previously, Cooley also assisted SiteOne during its $100 million Series C financing round.
Cooley LLP is known for partnering with clients on transformative deals and complex intellectual property and regulatory matters. The firm has nearly 1,400 lawyers across 19 offices worldwide.
This announcement is intended for informational purposes only and does not establish an attorney-client relationship with Cooley LLP or any affiliated entity. Readers are advised to seek professional legal advice independently.
